Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $VTGN #mentalhealth–Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today reported financial results for its fiscal year 2024 third quarter ended December 31, 2023 and provided a corporate update. “Momentum from clinical and corporate…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks